At least 165 COVID vaccines agents are under development in different countries, according to the WHO data. Some of them are in pre-clinical trials stage and some of them are in the final stage of human trials. It is the lower chances of success of vaccines that is why so many vaccines in the fray. Besides, it is also a very high-risk process.
The Russian candidate vaccine for COVID is reported to be ready for registration by August 10-12. Moscow’s Gamaleya Research Institute of Epidemiology and Microbiology developed vaccine is likely to be available for public use soon after the registration. This vaccine was, earlier this month, reported to have successfully completed human trials.
The Centre is said to have identified five sites across the country for late-stage clinical trials in human. The trial is expected to take place by the end of this year. Several COVID vaccine candidates, including those which are being developed by the University of Oxford, Zydus Cadila and Bharat Biotech, are expected to be included in the trials.
As part of the trials in the development of an indigenous vaccine for COVID, a 30-year-old man was given the first dose of COVAXIN at the AIMS in Delhi. Ethics committee will review the health condition of the volunteers who have been given sample doses. Among the 12 volunteers, 10 healthy individuals were selected for the vaccine to be given in phases.
The Indian Council of Medical Research has given approval to rapid antigen test kit developed by Mylab Discovery Solutions. This is first India made kit to diagnose coronavirus disease. The Pathocatch Covid-19 Antigen Rapid testing kit will be made available soon at a cost of around Rs 450. Antigen-based testing is being used to scale up the testing.
Indian drug manufacture that partner with the Oxford University research team in developing COVID vaccine announced its intention to conduct trials in India. The Serum Institute of India said it will apply for the approval to carry out trials in the country. The vaccine AZD1222 had a favourable response in the first phase of clinical trials in the UK.